{
    "Clinical Trial ID": "NCT01644890",
    "Intervention": [
        "INTERVENTION 1: ",
        "  NK105",
        "  received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle",
        "INTERVENTION 2: ",
        "  Paclitaxel",
        "  received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Written informed consent of the patient signed by herself.",
        "  Histologically confirmed metastatic or recurrent adenocarcinoma of the breast.",
        "  Aged 20 to 74 at the time of informed consent.",
        "Exclusion Criteria:",
        "  Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival",
        "  PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1.",
        "  Assessment period was from the day of randomisation until the first observation of lesion progression or death",
        "  Time frame: Baseline, every 6 weeks of study treatment period, and end of study,",
        "Results 1: ",
        "  Arm/Group Title: NK105",
        "  Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle",
        "  Overall Number of Participants Analyzed: 211",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  8.4        (7.0 to 9.9)",
        "Results 2: ",
        "  Arm/Group Title: Paclitaxel",
        "  Arm/Group Description: received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle",
        "  Overall Number of Participants Analyzed: 211",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  8.5        (6.9 to 11.5)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 34/214 (15.89%)",
        "  Leukocytosis 0/214 (0.00%)",
        "  Atrial fibrillation 0/214 (0.00%)",
        "  Cardiac failure congestive 0/214 (0.00%)",
        "  Pericardial effusion 1/214 (0.47%)",
        "  Cataract 0/214 (0.00%)",
        "  Macular fibrosis 0/214 (0.00%)",
        "  Constipation 2/214 (0.93%)",
        "  Diarrhoea 2/214 (0.93%)",
        "  Enterocolitis 0/214 (0.00%)",
        "  Ileus 1/214 (0.47%)",
        "  Nausea 3/214 (1.40%)",
        "Adverse Events 2:",
        "  Total: 27/213 (12.68%)",
        "  Leukocytosis 1/213 (0.47%)",
        "  Atrial fibrillation 1/213 (0.47%)",
        "  Cardiac failure congestive 1/213 (0.47%)",
        "  Pericardial effusion 0/213 (0.00%)",
        "  Cataract 1/213 (0.47%)",
        "  Macular fibrosis 1/213 (0.47%)",
        "  Constipation 1/213 (0.47%)",
        "  Diarrhoea 1/213 (0.47%)",
        "  Enterocolitis 1/213 (0.47%)",
        "  Ileus 0/213 (0.00%)",
        "  Nausea 0/213 (0.00%)"
    ]
}